Medtronic's Resolute DES shows good results in diabetics

Medtronic's ($MDT) Resolute drug-eluting stent showed strong results in diabetic patients with coronary artery disease through one year of follow-up, according to data presented this week at the Transcatheter Cardiovascular Therapeutics scientific symposium for interventional cardiovascular specialists. 

In a post-hoc pooled analysis of the Resolute clinical program, the outcomes of all 1,535 diabetes patients treated with a Resolute DES in 5 studies were compared with those of participants without the disease. The analysis also compared these outcomes to those of patients who received a Xience V DES from Abbott Laboratories ($ABT) in the randomized RESOLUTE All Comers trial.  
 
The analysis looked at the outcomes in insulin-dependent, non-insulin-dependent and patients without diabetes treated with a Resolute DES. The results show no observed differences between the Resolute and Xience arms after an adjustment.

And the results come as good news for diabetics with coronary disease. "People with diabetes and heart disease constitute about one-third of the patients that receive percutaneous coronary interventions worldwide," explained Prof. Sigmund Silber, director of the Heart Centre at the Isar in Munich, Germany. "They are an especially challenging group of patients to treat because of their increased risk of subsequent cardiovascular events, including heart attack and cardiac death, as well as repeat procedures in the target vessel."

Separately at the conference, Dr. David Kandzari of Piedmont Heart Institute in Atlanta discussed findings that show Medtronic's Endeavor zotarolimus-eluting stent outperformed Boston Scientific ($BSX) Taxus paclitaxel-eluting stent on measures of safety and efficacy through 5 years of clinical follow-up.

The findings come from ENDEAVOR IV, which involved roughly 1,550 patients and evaluated the two drug-eluting stents head-to-head.

"The five-year results from ENDEAVOR IV confirm that long-term clinical outcomes should be an essential consideration when making decisions related to stent selection," said Dr. Kandzari in a statement. "Interventionalists treating patients with coronary artery disease now have ample data to distinguish the important differences between the performance of these two drug-eluting stents."

- see Medtronic's release
- check out the release on Endeavor 

Suggested Articles

The clinical testing giant LabCorp will now begin rolling out a blood test for lung cancer developed by Resolution Bioscience.

Cognoa aims to equip pediatricians with an AI-powered app that can spot the signs of autism, allowing them to diagnose in the doctor's office.

Longitude Capital invests in what its founders call “transformative healthcare companies," working in areas they hope will increase quality of life.